Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Study Evaluating Single-Agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

NCT06496568 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT06496568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06496568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Study Evaluating Single-Agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 11, 2023
Completion date
July 21, 2027
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pik3ca-mutated cancers